Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown that the commonly used high-cholesterol drug simvastatin cannot slow disability progression.
Clinical trial: Cholesterol drug ineffective for treatment of multiple sclerosis
